Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Studies on the influence of the antihypertensive drug urapidil on blood circulation and its regulation in animal experiments (author's transl)].

× No keyword cloud information.

12 in total

1. Experimental studies on the neurocardiovascular effects of urapidil.

Authors: R A Gillis; K J Kellar; J A Quest; I J Namath; A Martino-Barrows; K Hill; P J Gatti; K Dretchen
Journal: Drugs Date: 1988 Impact factor: 9.546

2. Double-blind comparison of urapidil and prazosin in the treatment of patients with essential hypertension.

Authors: Y Kaneko
Journal: Drugs Date: 1988 Impact factor: 9.546

3. The place of alpha-adrenoceptor and beta-adrenoceptor blockade in the treatment of hypertension.

Authors: F Gross
Journal: Br J Clin Pharmacol Date: 1982-06 Impact factor: 4.335

4. Can we develop new drugs for hypertension?

Authors: F Gross
Journal: Br J Clin Pharmacol Date: 1982-01 Impact factor: 4.335

5. Proceedings of the joint meeting of the Scandinavian and British Pharmacological Societies. Stockholm--Sweden. 5th and 6th July, 1982.

Authors:
Journal: Br J Pharmacol Date: 1982-09 Impact factor: 8.739

6. Comparison of the antihypertensive effect of urapidil and metoprolol in hypertension.

Authors: G Leonetti; C Mazzola; S Boni; E Guffanti; A Meani; A Zanchetti
Journal: Eur J Clin Pharmacol Date: 1986 Impact factor: 2.953

7. The mechanism of the sympathoinhibitory action of urapidil: role of 5-HT1A receptors.

Authors: A G Ramage
Journal: Br J Pharmacol Date: 1991-04 Impact factor: 8.739

8. The influence of urapidil, a new antihypertensive agent, on cerebral perfusion pressure in dogs with and without intracranial hypertension.

Authors: H Van Aken; C Puchstein; C Anger; P Lawin
Journal: Intensive Care Med Date: 1983 Impact factor: 17.440

9. Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for alpha 1-adrenoceptor binding sites.

Authors: G Gross; G Hanft; N Kolassa
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1987-12 Impact factor: 3.000

10. Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus.

Authors: P Schoeffter; D Hoyer
Journal: Br J Pharmacol Date: 1988-11 Impact factor: 8.739